Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: DDRGK1

Gene summary for DDRGK1

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

DDRGK1

Gene ID

65992

Gene nameDDRGK domain containing 1
Gene AliasC20orf116
Cytomap20p13
Gene Typeprotein-coding
GO ID

GO:0001501

UniProtAcc

Q96HY6


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
65992DDRGK1P44T-EHumanEsophagusESCC9.73e-258.55e-010.1096
65992DDRGK1P47T-EHumanEsophagusESCC5.48e-378.22e-010.1067
65992DDRGK1P48T-EHumanEsophagusESCC2.33e-316.43e-010.0959
65992DDRGK1P49T-EHumanEsophagusESCC4.34e-161.59e+000.1768
65992DDRGK1P52T-EHumanEsophagusESCC1.94e-541.16e+000.1555
65992DDRGK1P54T-EHumanEsophagusESCC2.95e-359.85e-010.0975
65992DDRGK1P56T-EHumanEsophagusESCC3.81e-081.32e+000.1613
65992DDRGK1P57T-EHumanEsophagusESCC3.78e-541.08e+000.0926
65992DDRGK1P61T-EHumanEsophagusESCC3.28e-246.20e-010.099
65992DDRGK1P62T-EHumanEsophagusESCC5.26e-581.16e+000.1302
65992DDRGK1P65T-EHumanEsophagusESCC2.32e-378.53e-010.0978
65992DDRGK1P74T-EHumanEsophagusESCC6.64e-471.31e+000.1479
65992DDRGK1P75T-EHumanEsophagusESCC1.05e-791.62e+000.1125
65992DDRGK1P76T-EHumanEsophagusESCC1.66e-461.06e+000.1207
65992DDRGK1P79T-EHumanEsophagusESCC2.49e-541.05e+000.1154
65992DDRGK1P80T-EHumanEsophagusESCC1.31e-611.86e+000.155
65992DDRGK1P82T-EHumanEsophagusESCC2.52e-382.04e+000.1072
65992DDRGK1P83T-EHumanEsophagusESCC3.17e-742.49e+000.1738
65992DDRGK1P84T-EHumanEsophagusESCC3.06e-119.59e-010.0933
65992DDRGK1P89T-EHumanEsophagusESCC1.40e-231.91e+000.1752
Page: 1 2 3 4 5 6 7 8 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
Colorectum (GSE201348)The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.FAP: Familial adenomatous polyposis
CRC: Colorectal cancer
Colorectum (HTA11)The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AD: Adenomas
SER: Sessile serrated lesions
MSI-H: Microsatellite-high colorectal cancer
MSS: Microsatellite stable colorectal cancer
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
ProstateThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.BPH: Benign Prostatic Hyperplasia
SkinThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AK: Actinic keratosis
cSCC: Cutaneous squamous cell carcinoma
SCCIS:squamous cell carcinoma in situ
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:0042176ColorectumADregulation of protein catabolic process160/3918391/187231.06e-197.34e-17160
GO:0009896ColorectumADpositive regulation of catabolic process180/3918492/187234.33e-161.94e-13180
GO:1903362ColorectumADregulation of cellular protein catabolic process109/3918255/187232.14e-156.08e-13109
GO:0010498ColorectumADproteasomal protein catabolic process174/3918490/187233.18e-147.66e-12174
GO:0031331ColorectumADpositive regulation of cellular catabolic process156/3918427/187234.68e-141.05e-11156
GO:0009895ColorectumADnegative regulation of catabolic process124/3918320/187231.66e-133.35e-11124
GO:1903829ColorectumADpositive regulation of cellular protein localization110/3918276/187234.58e-138.44e-11110
GO:1903050ColorectumADregulation of proteolysis involved in cellular protein catabolic process92/3918221/187232.04e-123.19e-1092
GO:0031330ColorectumADnegative regulation of cellular catabolic process104/3918262/187232.66e-123.96e-10104
GO:0045732ColorectumADpositive regulation of protein catabolic process92/3918231/187233.85e-114.47e-0992
GO:0043161ColorectumADproteasome-mediated ubiquitin-dependent protein catabolic process141/3918412/187231.77e-101.68e-08141
GO:0045862ColorectumADpositive regulation of proteolysis129/3918372/187234.04e-103.46e-08129
GO:0051098ColorectumADregulation of binding126/3918363/187236.01e-104.88e-08126
GO:0031647ColorectumADregulation of protein stability108/3918298/187236.33e-105.08e-08108
GO:0022411ColorectumADcellular component disassembly147/3918443/187238.53e-106.76e-08147
GO:0042177ColorectumADnegative regulation of protein catabolic process55/3918121/187231.19e-098.85e-0855
GO:0061136ColorectumADregulation of proteasomal protein catabolic process75/3918187/187231.65e-091.20e-0775
GO:2000058ColorectumADregulation of ubiquitin-dependent protein catabolic process68/3918164/187231.82e-091.31e-0768
GO:1903363ColorectumADnegative regulation of cellular protein catabolic process39/391875/187232.69e-091.87e-0739
GO:0016236ColorectumADmacroautophagy103/3918291/187236.76e-094.15e-07103
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
DDRGK1SNVMissense_Mutationrs751324528c.490N>Tp.Arg164Cysp.R164CQ96HY6protein_codingdeleterious(0)probably_damaging(0.998)TCGA-AN-A046-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownSD
DDRGK1SNVMissense_Mutationc.559N>Ap.Glu187Lysp.E187KQ96HY6protein_codingdeleterious(0.03)probably_damaging(0.992)TCGA-C5-A1BM-01Cervixcervical & endocervical cancerFemale>=65I/IIUnknownUnknownSD
DDRGK1SNVMissense_Mutationnovelc.131N>Gp.Ala44Glyp.A44GQ96HY6protein_codingtolerated(0.14)benign(0.027)TCGA-C5-A8XH-01Cervixcervical & endocervical cancerFemale<65I/IIUnknownUnknownSD
DDRGK1SNVMissense_Mutationc.205G>Ap.Asp69Asnp.D69NQ96HY6protein_codingtolerated(1)benign(0.07)TCGA-AA-3984-01Colorectumcolon adenocarcinomaFemale<65I/IIUnknownUnknownSD
DDRGK1SNVMissense_Mutationrs763621314c.857N>Ap.Arg286Glnp.R286QQ96HY6protein_codingdeleterious(0.02)benign(0.041)TCGA-CK-4951-01Colorectumcolon adenocarcinomaFemale>=65I/IIUnknownUnknownPD
DDRGK1SNVMissense_Mutationnovelc.55N>Ap.Leu19Ilep.L19IQ96HY6protein_codingtolerated(0.3)benign(0)TCGA-A5-A1OF-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
DDRGK1SNVMissense_Mutationrs753666292c.367C>Tp.Arg123Trpp.R123WQ96HY6protein_codingdeleterious(0)probably_damaging(0.986)TCGA-AJ-A8CT-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
DDRGK1SNVMissense_Mutationc.750N>Tp.Gln250Hisp.Q250HQ96HY6protein_codingtolerated(0.05)benign(0.202)TCGA-AP-A0LM-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVChemotherapycisplatinSD
DDRGK1SNVMissense_Mutationrs764215113c.341N>Tp.Ser114Leup.S114LQ96HY6protein_codingdeleterious(0.05)benign(0)TCGA-AX-A2IO-01Endometriumuterine corpus endometrioid carcinomaFemale>=65I/IIChemotherapycarboplatinSD
DDRGK1SNVMissense_Mutationnovelc.813N>Gp.Ile271Metp.I271MQ96HY6protein_codingdeleterious(0)possibly_damaging(0.828)TCGA-B5-A1MX-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIHormone TherapymegaceSD
Page: 1 2 3 4 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
65992DDRGK1NUCLEAR HORMONE RECEPTORazathioprineAZATHIOPRINE21961091
Page: 1